Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Lonafarnib, sold under the brand name Zokinvy, is a medication used to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-deficient progeroid laminopathies in people one year of age and older. It is under trial for its use as combination treatment for Hepatitis D Virus.
History, Community, Culture & Applications
Explore the main themes, entities and connections around Lonafarnib. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
cancer treatment progeria phase clinical trials data patients drug use efficacy progeroid due certain trial medication zokinvy laminopathies hepatitis farnesyltransferase
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Lonafarnib | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Lonafarnib | ATC code | A16AX20 (WHO) | 1.00 | infobox |
| Lonafarnib | CAS Number | 193275-84-2 N | 1.00 | infobox |
| Lonafarnib | ChEBI | CHEBI:47097 N | 1.00 | infobox |
| Lonafarnib | ChEMBL | ChEMBL298734 Y | 1.00 | infobox |
| Lonafarnib | ChemSpider | 130645 Y | 1.00 | infobox |
| Lonafarnib | CompTox Dashboard (EPA) | DTXSID90172927 | 1.00 | infobox |
| Lonafarnib | DrugBank | DB06448 | 1.00 | infobox |
| Lonafarnib | ECHA InfoCard | 100.204.509 | 1.00 | infobox |
| Lonafarnib | Formula | C27H31Br2ClN4O2 | 1.00 | infobox |
| Lonafarnib | IUPHAR/BPS | 8024 | 1.00 | infobox |
| Lonafarnib | KEGG | D04768 Y | 1.00 | infobox |
| Lonafarnib | Legal status | US: ℞-only | 1.00 | infobox |
| Lonafarnib | Legal status | EU: Rx-only | 1.00 | infobox |
| Lonafarnib | License data | US DailyMed: Lonafarnib | 1.00 | infobox |
| Lonafarnib | Molar mass | 638.83 g·mol−1 | 1.00 | infobox |
| Lonafarnib | Other names | SCH 66336 | 1.00 | infobox |
| Lonafarnib | PDB ligand | 336 (PDBe, RCSB PDB) | 1.00 | infobox |
| Lonafarnib | PubChem CID | 148195 | 1.00 | infobox |
| Lonafarnib | Routes of administration | By mouth | 1.00 | infobox |
| Lonafarnib | Trade names | Zokinvy | 1.00 | infobox |
| Lonafarnib | UNII | IOW153004F | 1.00 | infobox |
| Lonafarnib | is a | synthetic tricyclic halogenated carboxamide with antineoplastic properties | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.